SiVEC in the News

  • SiVEC Winner of NIH TARGETED Delivery Challenge

    In a major triumph, SiVEC has secured victory in the highly competitive National Institutes of Health (NIH) TARGETED (Targeted Genome Editor Delivery) Challenge. The competition, designed to propel advancements in genome editing technology by sourcing innovative solutions for delivering genome editors to somatic cells, witnessed SiVEC rise to the occasion with unparalleled expertise. This remarkable accomplishment marks a significant stride forward in the ongoing pursuit of revolutionizing gene editing for the treatment of genetic diseases at their source.

  • SiVEC's CEO, Lyndsey Linke, was recently featured on the Integrate & Ignite Marketing Podcast

    Host Lori Jones and Lyndsey dive into her journey of co-founding SiVEC, a game-changing biotech company with a groundbreaking drug delivery platform, and how the team is making waves in the industry as a top emerging company. The interview also talks about the incredible ecosystem supporting technology development in Colorado! Join us for this exciting conversation about commercializing science, acquiring business acumen, and embracing a risk-taking mindset.

  • SiVEC’s CEO and co-founder, Dr. Lyndsey Linke, has been appointed as a new board member for the Colorado BioScience Association

    As a visionary health innovator who is passionate about building and growing successful life sciences companies in Colorado, Lyndsey is honored to be recognized as a respected leader in the life science’s community. She looks forward to beginning this new endeavor where she will work closely with CBSA, CBSA members, and Colorado’s life science community as they continue to gain momentum and advance Colorado’s life science ecosystem to the top 5!

  • SiVEC Biotechnologies awarded grant from the Colorado Office of Economic Development and International Trade

    Our exceptional team at SiVEC Biotechnologies has reached yet another milestone! The grant awarded by the Colorado Office of Economic Development and International Trade is a testament to SiVEC’s hard work and dedication to their mission of advancing nucleic acid and gene therapies with a focus on safe and precise tissue-targeted delivery. This $250,000 grant will enable SiVEC to advance a first-in-class cancer therapeutic targeting oncogenic-KRAS into IND-enabling stages.

  • SiVEC Biotechnologies wins first prize in the Innovator's Pitch Challenge Digital RESI March

    The Innovator’s Pitch Challenge allows early-stage companies to gain additional exposure to conference attendees and pitch directly to a panel of active investors and industry experts.

    The March event, a perennial highlight of RESI, featured more than 34 competing companies. Among the presenters, Dr. Lyndsey Linke (SiVEC CEO) was awarded the first place prize.

  • SiVEC Biotechnologies publishes paper on the safety and efficacy of its live bacterial delivery vehicle ​

    The new publication, published on February 5, 2023, appears in the journal Engineering in Life Sciences.

  • SiVEC Biotechnologies recognized as the 2022 Top Emerging Start-Up Company by BIO International

    SiVEC's CEO Lyndsey Linke participated in the BIO International Start-Up Stadium, a competition featuring live pitches from 42 finalist companies.